Romanian Journal of Laboratory Medicine (Jul 2024)

Assessment of ocrelizumab impact on neurofilament levels in multiple sclerosis patients

  • Maier Smaranda,
  • Huțanu Adina,
  • Bărcuțean Laura,
  • Sărmășan Emanuela,
  • Bălașa Rodica

DOI
https://doi.org/10.2478/rrlm-2024-0019
Journal volume & issue
Vol. 32, no. 3
pp. 245 – 254

Abstract

Read online

Multiple sclerosis (MS) is a debilitating neurological disease characterized by inflammation, demyelination, and neurodegeneration in the central nervous system. Despite extensive research, the pathology of MS remains incompletely understood. Ocrelizumab (OCRE), a monoclonal antibody targeting CD20-positive B cells, has shown efficacy in relapsing (RR) and primary progressive (PP) MS. Neurofilaments (Nf) are emerging biomarkers of neuroaxonal injury, reflecting disease activity and treatment response in MS. This study aimed to assess the impact of OCRE on serum Nf levels (NfLs) in RRMS and PPMS patients and explore factors influencing treatment response.

Keywords